Movatterモバイル変換

[0]ホーム
URL:

AU2001293233A1 - Aza heterocyclic derivatives and their therapeutic use - Google Patents

Aza heterocyclic derivatives and their therapeutic use

Info

Publication number
AU2001293233A1
AU2001293233A1AU2001293233AAU9323301AAU2001293233A1AU 2001293233 A1AU2001293233 A1AU 2001293233A1AU 2001293233 AAU2001293233 AAU 2001293233AAU 9323301 AAU9323301 AAU 9323301AAU 2001293233 A1AU2001293233 A1AU 2001293233A1
Authority
AU
Australia
Prior art keywords
sup
therapeutic use
heterocyclic derivatives
pharmaceutically acceptable
aza heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293233A
Inventor
Tim Machajewski
Sabina Pecci
Paul Renhowe
Cynthia Shafer
Mary-Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron CorpfiledCriticalChiron Corp
Publication of AU2001293233A1publicationCriticalpatent/AU2001293233A1/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Organic compounds having the structural formula I are provided where the variables have the values described herein and R<SUP>1 </SUP>and R<SUP>2 </SUP>join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
AU2001293233A2000-09-012001-08-30Aza heterocyclic derivatives and their therapeutic useAbandonedAU2001293233A1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US23182900P2000-09-012000-09-01
US60/231,8292000-09-01
PCT/US2001/041942WO2002018383A2 (en)2000-09-012001-08-30Aza heterocyclic derivatives and their therapeutic use

Publications (1)

Publication NumberPublication Date
AU2001293233A1true AU2001293233A1 (en)2002-03-13

Family

ID=22870779

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2001293233AAbandonedAU2001293233A1 (en)2000-09-012001-08-30Aza heterocyclic derivatives and their therapeutic use

Country Status (9)

CountryLink
US (4)US6756383B2 (en)
EP (1)EP1313734B1 (en)
JP (2)JP4341949B2 (en)
AT (1)ATE448226T1 (en)
AU (1)AU2001293233A1 (en)
DE (1)DE60140456D1 (en)
ES (1)ES2334641T3 (en)
PT (1)PT1313734E (en)
WO (1)WO2002018383A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2001293233A1 (en)2000-09-012002-03-13Chiron CorporationAza heterocyclic derivatives and their therapeutic use
ES2250480T3 (en)2000-09-112006-04-16Chiron Corporation DERIVATIVES OF QUINOLINONE AS INHIBITORS OF TYROSINE QUINASA.
US20030028018A1 (en)*2000-09-112003-02-06Chiron CoporationQuinolinone derivatives
JP2004536113A (en)*2001-07-032004-12-02カイロン コーポレイション Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase
US7642278B2 (en)*2001-07-032010-01-05Novartis Vaccines And Diagnostics, Inc.Indazole benzimidazole compounds
US7825132B2 (en)*2002-08-232010-11-02Novartis Vaccines And Diagnostics, Inc.Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en)*2002-08-232005-11-17Chiron CorporationCombination therapy with CHK1 inhibitors
WO2004018419A2 (en)2002-08-232004-03-04Chiron CorporationBenzimidazole quinolinones and uses thereof
AU2003275282A1 (en)*2002-09-302004-04-23Bristol-Myers Squibb CompanyNovel tyrosine kinase inhibitors
NZ539425A (en)*2002-11-132007-11-30Chiron CorpMethods of treating cancer and related methods
WO2004063151A2 (en)*2003-01-032004-07-29Bristol-Myers Squibb CompanyNovel tyrosine kinase inhibitors
US7329678B2 (en)*2003-01-282008-02-12Smithkline Beecham CorporationChemical compounds
EP1608369B1 (en)*2003-03-282013-06-26Novartis Vaccines and Diagnostics, Inc.Use of organic compounds for immunopotentiation
EP1692085A4 (en)*2003-11-072010-10-13Novartis Vaccines & Diagnostic INHIBITION OF FGFR3 RECEPTOR AND TREATMENT OF MULTIPLE MYELOMA
FR2862969A1 (en)2003-11-282005-06-03Oreal PROCESS FOR THE PREPARATION OF NITROGEN-SUBSTITUTED PYRROLIDINYL GROUP PARAPHENYLENEDIAMINE DERIVATIVES AND INTERMEDIATE COMPOUNDS
EP1718306A2 (en)*2004-02-202006-11-08Chiron CorporationModulation of inflammatory and metastatic processes
AU2006208012B2 (en)*2005-01-272011-08-04Novartis Vaccines And Diagnostics Inc.Treatment of metastasized tumors
US7538113B2 (en)2005-02-182009-05-26Wyeth4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en)2005-02-182009-09-01Wyeth7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en)2005-02-182009-05-19WyethImidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
CN101203529A (en)2005-02-182008-06-18诺华疫苗和诊断公司 Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2351772B1 (en)2005-02-182016-07-13GlaxoSmithKline Biologicals SAProteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
CN101222850B (en)2005-05-132012-10-03诺瓦提斯公司 Ways to treat cancers that are resistant to drugs
JP5545925B2 (en)*2005-05-172014-07-09ノバルティス アーゲー Method for synthesizing heterocyclic compounds
US7531542B2 (en)2005-05-182009-05-12WyethBenzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
NZ563692A (en)2005-05-232011-04-29Novartis AgCrystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US7582636B2 (en)2005-05-262009-09-01WyethPiperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP2614709A1 (en)2005-07-182013-07-17Novartis AGSmall animal model for HCV replication
WO2007031838A1 (en)2005-09-162007-03-22Ranbaxy Laboratories LimitedSubstituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
ATE539765T1 (en)2005-11-042012-01-15Novartis Vaccines & Diagnostic FLU VACCINES WITH PARTICLE ADJUVANTS AND IMMUNE BOOSTERS COMBINATIONS
JP2009514850A (en)2005-11-042009-04-09ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
WO2007052056A1 (en)2005-11-042007-05-10Novartis Vaccines And Diagnostics SrlAdjuvanted influenza vaccines including cytokine-inducing agents
US10842867B2 (en)2005-11-042020-11-24Seqirus UK LimitedAdjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AR062545A1 (en)2005-11-292008-11-19Novartis Ag STABLE FORMULATIONS OF QUINOLINONES
AU2006321602B2 (en)2005-12-082012-03-08Novartis AgEffects of inhibitors of FGFR3 on gene transcription
KR20110110853A (en)2006-01-272011-10-07노파르티스 파르마 아게 Influenza Vaccine Containing Hemagglutinin and Matrix Proteins
ATE539079T1 (en)2006-03-232012-01-15Novartis Ag IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
CA2646349A1 (en)2006-03-242007-10-04Novartis Vaccines And Diagnostics Gmbh & Co KgStorage of influenza vaccines without refrigeration
EP2019686B1 (en)2006-03-312012-07-11Novartis AGCombined mucosal and parenteral immunization against hiv
US20100015168A1 (en)2006-06-092010-01-21Novartis AgImmunogenic compositions for streptococcus agalactiae
GB0614460D0 (en)2006-07-202006-08-30Novartis AgVaccines
GB0614471D0 (en)2006-07-202006-08-30Syngenta LtdHerbicidal Compounds
EP2586790A3 (en)2006-08-162013-08-14Novartis AGImmunogens from uropathogenic Escherichia coli
ES3031467T3 (en)2006-09-112025-07-09Seqirus Uk LtdMaking influenza virus vaccines without using eggs
PL2121011T3 (en)2006-12-062014-10-31Novartis AgVaccines including antigen from four strains of influenza virus
GB0700562D0 (en)2007-01-112007-02-21Novartis Vaccines & DiagnosticModified Saccharides
WO2009001217A2 (en)2007-06-272008-12-31Novartis AgLow-additive influenza vaccines
GB0713880D0 (en)2007-07-172007-08-29Novartis AgConjugate purification
GB0714963D0 (en)2007-08-012007-09-12Novartis AgCompositions comprising antigens
GB0810305D0 (en)2008-06-052008-07-09Novartis AgInfluenza vaccination
GB0818453D0 (en)2008-10-082008-11-12Novartis AgFermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0800855D0 (en)*2008-01-172008-02-27Syngenta LtdHerbicidal compounds
NZ587798A (en)2008-03-182013-06-28Novartis AgImprovements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
AU2010220103A1 (en)2009-03-062011-09-22Novartis AgChlamydia antigens
CN109248313B (en)2009-04-142023-01-17葛兰素史密丝克莱恩生物有限公司Compositions for immunization against staphylococcus aureus
WO2010125461A1 (en)2009-04-272010-11-04Novartis AgAdjuvanted vaccines for protecting against influenza
AU2010269961A1 (en)2009-07-072012-02-02Novartis AgConserved Escherichia coli immunogens
PL3178490T3 (en)2009-07-152022-08-01Glaxosmithkline Biologicals S.A.Rsv f protein compositions and methods for making same
ES2670799T3 (en)2009-07-162018-06-01Glaxosmithkline Biologicals Sa Detoxified immunogens from Escherichia coli
GB0918392D0 (en)2009-10-202009-12-02Novartis AgDiagnostic and therapeutic methods
WO2011051212A1 (en)*2009-10-282011-05-05Basf SeUse of heteroaromatic compounds as herbicides
GB0919690D0 (en)2009-11-102009-12-23Guy S And St Thomas S Nhs Founcompositions for immunising against staphylococcus aureus
EP2519265B1 (en)2009-12-302018-11-14GlaxoSmithKline Biologicals SAPolysaccharide immunogens conjugated to e. coli carrier proteins
JP2013532008A (en)2010-05-282013-08-15テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en)2010-06-112010-07-21Novartis AgOMV vaccines
US9192661B2 (en)2010-07-062015-11-24Novartis AgDelivery of self-replicating RNA using biodegradable polymer particles
ES3021243T3 (en)2011-01-262025-05-26Glaxosmithkline Biologicals SaRsv immunization regimen
LT3275892T (en)2011-05-132020-04-10Glaxosmithkline Biologicals S.A.Pre-fusion rsv f antigens
ES2602813T3 (en)*2011-06-092017-02-22Rhizen Pharmaceuticals S.A. New compounds as modulators of GPR-119
WO2013009564A1 (en)2011-07-082013-01-17Novartis AgTyrosine ligation process
JP6170932B2 (en)2011-11-072017-07-26ノバルティス アーゲー Carrier molecule comprising spr0096 antigen and spr2021 antigen
WO2013108272A2 (en)2012-01-202013-07-25International Centre For Genetic Engineering And BiotechnologyBlood stage malaria vaccine
AU2013326584B2 (en)2012-10-022016-12-01Glaxosmithkline Biologicals SaNonlinear saccharide conjugates
EP2870974A1 (en)2013-11-082015-05-13Novartis AGSalmonella conjugate vaccines
EP2977374A1 (en)*2014-07-212016-01-27Université de StrasbourgMolecules presenting dual emission properties
ES2872555T3 (en)*2015-06-252021-11-02Univ Health Network HPK1 inhibitors and methods of using them
CN107935858B (en)*2016-10-122020-09-08利尔化学股份有限公司Preparation method of 5-fluoro-2-nitrophenol
JP7329510B2 (en)*2017-11-242023-08-18ヤンセン ファーマシューティカ エヌ．ベー． pyrazolopyridinone compound
MX2020005344A (en)*2017-11-242020-08-13Janssen Pharmaceutica NvPyrazolopyridinone compounds.
WO2020135483A1 (en)2018-12-262020-07-02Janssen Pharmaceutica NvThienopyridinone compounds
CA3175420A1 (en)*2020-04-132021-10-21Mark R. BrayMethods for treating cytokine release syndrome
TW202246284A (en)*2021-03-102022-12-01大陸商山東軒竹醫藥科技有限公司Tricyclic hpk1 inhibitor and use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE290153C (en)
DE2363459A1 (en)1973-12-201975-06-26Basf Ag7-Amino-quinoline cpds. - for use as optical brighteners, dyes, colour formers in copying and in printing pastes
DE3634066A1 (en)1986-10-071988-04-21Boehringer Mannheim Gmbh NEW 5-ALKYLBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
US5073492A (en)1987-01-091991-12-17The Johns Hopkins UniversitySynergistic composition for endothelial cell growth
DE3739366A1 (en)1987-04-101988-10-27Boehringer Mannheim Gmbh DESAZA-PURIN-NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN NUCLEIC ACID SEQUENCING AND AS AN ANTIVIRAL AGENT
JPH0699497B2 (en)1987-04-161994-12-07富士写真フイルム株式会社 Photopolymerizable composition
GB8709448D0 (en)1987-04-211987-05-28Pfizer LtdHeterobicyclic quinoline derivatives
DE3932953A1 (en)1989-10-031991-04-11Boehringer Mannheim Gmbh NEW 2-BICYCLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
GB9107742D0 (en)1991-04-111991-05-29Rhone Poulenc AgricultureNew compositions of matter
GB9108369D0 (en)1991-04-181991-06-05Rhone Poulenc AgricultureCompositions of matter
GB9108547D0 (en)1991-04-221991-06-05Fujisawa Pharmaceutical CoQuinoline derivatives
USRE37650E1 (en)1991-05-102002-04-09Aventis Pharmacetical Products, Inc.Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en)1991-05-101998-01-20Rhone-Poulenc Rorer Pharmaceuticals Inc.Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en)1991-05-101996-01-02Rhone-Poulenc Rorer Pharmaceuticals Inc.Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en)*1991-05-101997-10-08Rhone-Poulenc Rorer International (Holdings) Inc.Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5856115A (en)1991-05-241999-01-05Fred Hutchinson Cancer Research CenterAssay for identification therapeutic agents
DE4129603A1 (en)*1991-09-061993-03-11Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
ATE239506T1 (en)1992-03-052003-05-15Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
JP3142378B2 (en)1992-06-222001-03-07ティーディーケイ株式会社 Organic EL device
US5330992A (en)*1992-10-231994-07-19Sterling Winthrop Inc.1-cyclopropyl-4-pyridyl-quinolinones
US5981569A (en)1992-11-131999-11-09Yissum Research Development Company Of The Hebrew University Of JerusalemSubstituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en)1992-11-131998-08-11Sugen, Inc.Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en)1992-11-131998-06-09Sugen, Inc.Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (en)1993-07-281995-02-14Toyobo Co LtdPhotopolymerizable composition
AU5881394A (en)1994-01-081995-08-01Rhone-Poulenc Agriculture LimitedBenzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (en)1994-07-111996-02-02Toyobo Co LtdPhotopolymerized composition
JP3441246B2 (en)1995-06-072003-08-25富士写真フイルム株式会社 Photopolymerizable composition
GB9514265D0 (en)1995-07-131995-09-13Wellcome FoundHetrocyclic compounds
GB9624482D0 (en)1995-12-181997-01-15Zeneca Phaema S AChemical compounds
DE69734149T2 (en)1996-03-152006-07-06Astrazeneca Ab CINOLINE DERIVATIVES AND USE AS CEREALS
DE19610723A1 (en)1996-03-191997-09-25Bayer Ag Electroluminescent devices using glare systems
US5942385A (en)1996-03-211999-08-24Sugen, Inc.Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en)1996-06-192011-09-27Rhone Poulenc Rorer LimitedSubstituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
KR20000022040A (en)1996-06-202000-04-25보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템Compounds and methods for providing pharmacologically active preparations and uses thereof
ATE300521T1 (en)1996-09-252005-08-15Astrazeneca Ab QUINOLINE DERIVATIVES THAT DELAY THE EFFECT OF GROWTH FACTORS LIKE VEGF
WO1999010349A1 (en)1997-08-221999-03-04Zeneca LimitedOxindolylquinazoline derivatives as angiogenesis inhibitors
WO2000012089A1 (en)*1998-08-312000-03-09Merck & Co., Inc.Novel angiogenesis inhibitors
DE19756235A1 (en)*1997-12-171999-07-01Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
WO1999050263A1 (en)1998-03-311999-10-07Warner-Lambert CompanyQuinolones as serine protease inhibitors
AU3850299A (en)1998-05-201999-12-06Kyowa Hakko Kogyo Co. Ltd.Vegf activity inhibitors
DE69919707T2 (en)1998-06-192005-09-01Chiron Corp., Emeryville GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
CA2333647A1 (en)1998-06-292000-01-06Dupont Pharmaceuticals CompanyCyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (en)1998-07-152001-09-07Lafon Labor PHARMACEUTICAL COMPOSITIONS COMPRISING 2-QUINOLONES
DE19841985A1 (en)1998-09-032000-03-09Schering AgNew heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis
AU1099000A (en)1998-10-052000-04-26Axys Pharmaceuticals, Inc.Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en)1998-11-081999-09-22Yeda Res & DevPharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (en)1999-03-312003-02-25주식회사 엘지화학New organometallic complexes for use in light emitting devices
CN1351498B (en)1999-05-212012-08-15布里斯托尔-迈尔斯斯奎布公司Pyrrolotriazines inhibitors of kinases
PE20010306A1 (en)1999-07-022001-03-29Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
AU778042B2 (en)1999-10-192004-11-11Merck & Co., Inc.Tyrosine kinase inhibitors
WO2001029025A2 (en)1999-10-192001-04-26Merck & Co., Inc.Tyrosine kinase inhibitors
JP2003520254A (en)2000-01-192003-07-02エス． ジル，パーカッシュ Methods and compositions relating to antisense VEGF oligonucleotides
GB0001930D0 (en)2000-01-272000-03-22Novartis AgOrganic compounds
US6313138B1 (en)2000-02-252001-11-06Merck & Co., Inc.Tyrosine kinase inhibitors
AU778417B2 (en)2000-02-252004-12-02Merck & Co., Inc.Tyrosine kinase inhibitors
US6420382B2 (en)2000-02-252002-07-16Merck & Co., Inc.Tyrosine kinase inhibitors
AU2001293233A1 (en)2000-09-012002-03-13Chiron CorporationAza heterocyclic derivatives and their therapeutic use
US20030028018A1 (en)2000-09-112003-02-06Chiron CoporationQuinolinone derivatives
ES2250480T3 (en)2000-09-112006-04-16Chiron Corporation DERIVATIVES OF QUINOLINONE AS INHIBITORS OF TYROSINE QUINASA.
CA2424689A1 (en)2000-10-172002-04-25Merck & Co., Inc.Orally active salts with tyrosine kinase activity
JP2004536113A (en)2001-07-032004-12-02カイロン コーポレイション Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase
WO2004018419A2 (en)2002-08-232004-03-04Chiron CorporationBenzimidazole quinolinones and uses thereof
AU2003275282A1 (en)2002-09-302004-04-23Bristol-Myers Squibb CompanyNovel tyrosine kinase inhibitors
NZ539425A (en)2002-11-132007-11-30Chiron CorpMethods of treating cancer and related methods
EP1608369B1 (en)2003-03-282013-06-26Novartis Vaccines and Diagnostics, Inc.Use of organic compounds for immunopotentiation
US6774327B1 (en)2003-09-242004-08-10Agilent Technologies, Inc.Hermetic seals for electronic components
EP1692085A4 (en)2003-11-072010-10-13Novartis Vaccines & Diagnostic INHIBITION OF FGFR3 RECEPTOR AND TREATMENT OF MULTIPLE MYELOMA
WO2005053692A1 (en)2003-12-012005-06-16The Scripps Research InstituteAdvanced quinolinone based protein kinase inhibitors
AU2006208012B2 (en)2005-01-272011-08-04Novartis Vaccines And Diagnostics Inc.Treatment of metastasized tumors

Also Published As

Publication numberPublication date
ATE448226T1 (en)2009-11-15
US6759417B2 (en)2004-07-06
US7368459B2 (en)2008-05-06
DE60140456D1 (en)2009-12-24
US20040002518A1 (en)2004-01-01
JP2004507543A (en)2004-03-11
WO2002018383A2 (en)2002-03-07
JP2007217427A (en)2007-08-30
US20050137188A1 (en)2005-06-23
PT1313734E (en)2010-02-09
ES2334641T3 (en)2010-03-15
US20020103230A1 (en)2002-08-01
EP1313734A2 (en)2003-05-28
US6756383B2 (en)2004-06-29
JP4341949B2 (en)2009-10-14
US7138409B2 (en)2006-11-21
WO2002018383A3 (en)2002-08-29
EP1313734B1 (en)2009-11-11
US20070032528A1 (en)2007-02-08

Similar Documents

PublicationPublication DateTitle
AU2001293233A1 (en)Aza heterocyclic derivatives and their therapeutic use
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
YU69902A (en)New piperazine derivatives
BG103945A (en)Derivatives of 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
WO2003013484A3 (en)N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
DE69528005D1 (en) Prolineamid derivatives
DE69933573D1 (en) CHINAZOLINE DERIVATIVES AS MEDICAMENTS
CA2216796A1 (en)Quinazoline derivatives
IL124537A0 (en)Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
ATE194335T1 (en) 4,5-DIARYLOXAZOLE DERIVATIVES
HUP0300641A2 (en)Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions containing the same as the active ingredient
GB9914486D0 (en)Medicaments
AU1247195A (en)Cyclic amide derivatives as neurokinin a antagonists
AP9801378A0 (en)9-amino-3- keto erythromycin derivatives.
KR960701878A (en) Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents
EA200200119A1 (en) β-CARBOLINE DRUGS
SE0300908D0 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
CA2386813A1 (en)Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
FI101227B1 (en) Process for Preparation of Pharmaceutically Active 4-Deoxy-4-Epipodophyllotoxin Derivatives
MY133112A (en)3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
YU30603A (en)Bridged piperazine derivatives
AP9801377A0 (en)Tricyclic erythromycin derivatives.
DE69330601D1 (en) SEROTON INERGIC ERGOLIN DERIVATIVES
MXPA02004441A (en)Isoxazole derivatives to be used as phosphodiesterase vii inhibitors.
MD1744F2 (en) Clavulanic acid salts and process for obtaining them
[8]ページ先頭
©2009-2025 Movatter.jp